Table 1.
Variable | All (n = 385) | Not CAIX >1% and high vascular density (n = 322) | CAIX >1% and high vascular density (n = 63) | P* |
---|---|---|---|---|
Age (years)a | 64.0 (34.0–89.0) | 64.3 (34.0–89.0) | 63.5 (43.0–88.0) | 0.634 |
Follow-up (months)a | 65.1 (0.0–156.0) | 63.8 (0.0–156.0) | 71.6 (0–148.0) | 0.125 |
Grade | ||||
Low | 318 (82.6) | 270 (83.9) | 48 (76.2) | 0.142 |
High | 67 (17.4) | 52 (16.1) | 15 (23.8) | |
Histology | ||||
EEC | 372 (96.6) | 314 (97.5) | 58 (92.1) | 0.028 |
NEEC | 13 (3.4) | 8 (2.5) | 5 (7.9) | |
FIGO stage | ||||
I–II | 363 (93.8) | 305 (94.7) | 58 (92.1) | 0.406 |
III–IV | 22 (5.7) | 17 (5.3) | 5 (7.9) | |
Myometrial invasion | ||||
<50% | 258 (67.2) | 218 (67.9) | 40 (63.5) | 0.494 |
≥50% | 126 (32.8) | 103 (32.1) | 23 (36.5) | |
LVSIb | ||||
No | 243 (62.8) | 200 (90.1) | 43 (84.3) | 0.234 |
Yes | 30 (7.8) | 22 (9.9) | 8 (15.7) | |
Lymph nodesc | ||||
No metastasis | 263 (68.0) | 223 (95.7) | 40 (95.2) | 0.891 |
Metastasis | 12 (3.1) | 10 (4.3) | 2 (4.8) | |
Adjuvant treatment | ||||
No | 154 (40.0) | 143 (44.8) | 22 (34.9) | |
Radiotherapy | 200 (51.9) | 161 (50.0) | 39 (61.9) | 0.084 |
Chemotherapy | 31 (8.1) | 18 (5.6) | 2 (3.2) | 0.429 |
Recurrence | ||||
No | 338 (87.8) | 289 (89.8) | 49 (77.8) | |
Yes | 47 (12.2) | 33 (10.2) | 14 (22.2) | 0.008 |
Local | 14 (3.6) | 12 (3.7) | 2 (3.2) | 0.830 |
Regional | 16 (4.2) | 13 (4.0) | 3 (4.8) | 0.792 |
Distant | 31 (8.1) | 19 (5.9) | 12 (19.0) | <0.001 |
Death | ||||
No | 335 (87.0) | 284 (88.2) | 49 (77.8) | |
Yes | 50 (13.0) | 38 (11.8) | 14 (22.2) | 0.027 |
EC-related | 21 (5.5) | 12 (3.7) | 11 (17.5) | <0.001 |
CAIX carbonic anhydrase IX, EEC endometrioid endometrial carcinoma, NEEC non-endometrioid endometrial carcinoma, FIGO International Federation of Gynaecology and Obstetrics, LVSI lymphovascular space invasion, EC endometrial carcinoma
*P value of the Mann–Whitney U test for continuous, and χ2 test and Fisher’s exact for categorical variables
aMedian values (range)
bBased on 273 patients
cBased on 275 patients